ID: MRFR/HC/6380-HCR | February 2021 | Region: Global | 90 pages
The cancer registry software market is expected to grow significantly over the forecast period. The market held a market value of USD 56.4 million in 2018 and is projected to grow at a CAGR of 10.7% over the forecast period.
Increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance are positively affecting market growth.
On the other hand, privacy and data security-related concerns and reluctance to adopt advanced solutions are likely to hamper the growth of the market.
The cancer registry software market has been segmented into type, deployment model, database type, functionality, and end user.
By type, the market has been segmented into integrated software and standalone software.
Based on the deployment model, the market has been segmented into cloud-based models and on-premise models.
On the basis of the database type, the market has been segmented into commercial databases and public databases.
By functionality, the market has been segmented into patient care management, product outcome evaluation, cancer reporting to meet state and federal regulations, medical research & clinical studies.
The market, by end user, has been segmented into hospitals & medical practices, government organizations & research centers, pharmaceutical, biotechnology, and medical device companies, and others.
The cancer registry software market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cancer registry software market has been segmented into Western Europe and Eastern Europe. Western Europe market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The cancer registry software market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Cancer registry software market, by Key Players
Regional Market Summary Cancer registry software market Share (%), by Region, 2018
Source: White Papers, Company Presentations, Annual Reports
On a regional basis, the Americas is anticipated to dominate the cancer registry software market owing to the rising prevalence of cancer, innovative product development and increasing investment in research and development for innovation in the region. According to the National Cancer Institute, there were 1,735,350 new cases of cancer in the US in 2018.
Europe is expected to hold the second largest position in the market owing to the presence of strong academic & research base and availability of funding for research in the European countries.
Asia-Pacific is anticipated to be the fastest growing region in the market owing to the shift of pharmaceutical companies to countries such as India and China, which are low-cost manufacturing regions.
The Middle East & Africa has the least share of the cancer registry software market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
by Deployment Model
by Database Type
by End User
Frequently Asked Questions (FAQ) :
Cancer Registry Software Market was valued at USD 56.4 million in 2018.
The market is expected to exhibit a strong 10.7% CAGR over the forecast period from 2019 to 2024.
The increasing prevalence of cancer and the increasing adoption of electronic healthcare record systems are the major drivers for the global cancer registry software market.
Concerns related to data privacy are the major restraint on the cancer registry software market.
The Americas and Europe dominate the global cancer registry software market due to the widespread adoption of EHR systems.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.